Welcome to our dedicated page for Ww Intl news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on Ww Intl stock.
WW International Inc (WW) delivers science-based weight management solutions through digital platforms, workshops, and clinical partnerships. This page aggregates all corporate announcements and verified news coverage for investors and industry observers.
Access primary-source press releases, earnings reports, and strategic updates to monitor WW’s market position. Our curated collection ensures timely access to operational developments, including product launches, leadership changes, and partnership announcements.
Key updates include quarterly financial results, clinical program expansions, technology enhancements, and wellness industry analysis. Each entry provides context to help stakeholders assess WW’s evolving role in digital health and behavioral science.
Bookmark this page for streamlined tracking of WW’s corporate milestones and sector influence. Check back regularly for authoritative updates directly from the company and trusted financial publications.
WeightWatchers has announced a strategic pharmacy integration with LillyDirect's provider Gifthealth to streamline access to Zepbound weight management medication. The partnership enables real-time prescription tracking and simplified fulfillment for WeightWatchers Clinic members through the WeightWatchers App.
Key highlights:
- 33% of WeightWatchers Clinic members currently use Zepbound
- Zepbound vial prescriptions have increased by over 100% in recent months
- A study of 3,260 WeightWatchers Clinic patients showed 21% average body weight loss at 12 months
The integration specifically benefits self-pay patients without insurance coverage by offering Zepbound vials at more affordable prices. This move aligns with WeightWatchers' holistic approach to weight management, combining medication access with their proven behavioral tools and community support system.
WW International reported Q4 2024 results with revenues of $184.4 million and net income of $25.1 million. Total subscribers reached 3.3 million, including 92,000 Clinical subscribers, up 37.8% year-over-year. While subscription revenues declined 7.3%, Clinical subscription revenues grew 57.9% to $20.5 million.
Q4 highlights include improved gross margin of 69.7% (up 906 basis points) and operating income of $36.2 million. The company appointed Tara Comonte as permanent President and CEO.
Full year 2024 showed mixed results with revenues of $785.9 million and a net loss of $345.7 million, including $293.2 million in non-cash impairment charges. The company remains focused on cost management, targeting $100 million in run-rate savings by end of 2025.
WW International (NASDAQ: WW) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025, after market close. The company will host a conference call at 5:00 p.m. ET on the same day.
During the call, Interim President and CEO Tara Comonte and CFO Felicia DellaFortuna will discuss the results and take questions from investors. The webcast will be available on corporate.ww.com under Events and Presentations, with supplemental investor materials provided before the call. A replay will be accessible for approximately 90 days.
WeightWatchers (WW) has launched a next-generation program featuring advanced AI-powered features and expanded nutrition support. The program introduces insurance-covered access to registered dietitians, AI-powered food scanning and recipe analysis tools, and over 150 new ZeroPoint® foods. Key features include personalized nutrition counseling, macro-nutrient tracking, and seamless Points® calculation through photo recognition.
The program complements WW's recent expansion into clinical solutions, including access to weight-loss medications. Studies show members using the Points Program alongside medications achieve 56% more weight loss than those using medications alone. The company reports that members experience a 20% improvement in quality of life with their enhanced model of care.
WW International (NASDAQ: WW) has appointed Felicia DellaFortuna as Chief Financial Officer, effective January 1, 2025, replacing Heather Stark who will depart on December 27, 2024. DellaFortuna brings significant financial leadership experience, having previously served as CFO at Enthusiast Gaming and BuzzFeed, where she drove operational efficiency and profitability. At BuzzFeed, she led key acquisitions including Complex Networks and HuffPost, while diversifying revenue streams. The appointment comes during what the company describes as a critical transformation period as it adapts to rapidly evolving industry conditions.
WW International reported Q3 2024 results with revenues of $192.9 million, down 10.2% year-over-year. The company posted an operating loss of $39.0 million compared to operating income of $30.6 million in the prior year. End of Period Subscribers decreased 8.8% to 3.7 million. Clinical Subscribers grew 71.5% to 78,000. Adjusted gross margin improved to 69.1%. The company recorded non-cash impairment charges of $57.0 million for franchise rights. WW reiterated its full year 2024 guidance, expecting year-end subscribers of at least 3.1 million and revenue of at least $770.0 million.
WW International (NASDAQ: WW) has announced it will release its third quarter 2024 financial results before market open on Wednesday, November 6, 2024. The company will host a conference call at 8:30 a.m. ET on the same day, featuring Interim President and CEO Tara Comonte and CFO Heather Stark, who will discuss the results and address questions from investors. A live webcast will be available on corporate.ww.com, along with supplemental investor materials, and will remain accessible for approximately 90 days.
WeightWatchers (NASDAQ: WW) has announced the addition of compounded semaglutide to its weight management program, starting at $129. This expansion aims to enhance accessibility and affordability of weight loss medications amid ongoing shortages of branded GLP-1 drugs. The company's offering combines clinical interventions with behavioral support, including access to board-certified clinicians, registered dietitians, and the WeightWatchers community.
Key points:
- WeightWatchers partnered with an FDA-registered 503B facility to ensure quality and safety
- The company conducted nearly 3 million stock checks, finding GLP-1 medications in stock only 4.5% of the time
- 45% of eligible WeightWatchers Clinic members were denied insurance coverage for GLP-1 medications
- Members using GLP-1 medications with the Points® Program lose 11% more weight than those using medications alone
- Compounded semaglutide will be available to eligible members within 1-3 business days
WeightWatchers (NASDAQ: WW) announced a significant leadership change on Sept. 27, 2024. Tara Comonte, an independent board member, has been appointed as Interim Chief Executive Officer, succeeding Sima Sistani, who is stepping down from her roles as CEO and board member.
During her tenure, Sistani led the company's transformation into a modern digital health organization and expanded its portfolio with the acquisition of Sequence (now WeightWatchers Clinic). Comonte, with her extensive executive leadership experience, is expected to guide the company's transformation, sharpen its strategic focus, and evolve its offerings to drive growth.
The company reaffirmed its full-year 2024 guidance for End of Period Subscribers, Revenue, Adjusted Operating Income, and Adjusted EBITDAS. The WeightWatchers Board of Directors has been reduced from nine to eight members following this transition.
WeightWatchers (NASDAQ: WW) has announced two strategic leadership appointments to drive growth and community engagement. Scott Honken joins as Chief Commercial Officer, overseeing B2B growth, operations, partnerships, and licensing. Phillip Picardi becomes Chief Impact Officer, focusing on building communities and scaling the company's impact work.
Honken, formerly at Calibrate, brings experience from Rightway and Livongo in forming multimillion-dollar partnerships. Picardi, previously Chief Strategy Officer at the Los Angeles LGBT Center, will lead brand marketing, communications, social impact, and employee experience teams.
These appointments align with WeightWatchers' goal to expand access to equitable care and redefine community engagement across all stakeholders, including employers, payers, and health plans.
FAQ
What is the current stock price of Ww Intl (WW)?
What is the market cap of Ww Intl (WW)?
